NovoCure Limited (NVCR) IPO Opens Lower

Today's IPO for NovoCure Limited (Nasdaq: NVCR) opened for trading at $20.16 after pricing 12,500,000 shares of its common stock at $22, below the $23-$24 revised IPO range. Shares last traded at $19.

J.P. Morgan Securities LLC, Deutsche Bank Securities and Evercore Group L.L.C. are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC is acting as lead manager and JMP Securities LLC and Wedbush PacGrow are acting as co-managers. Perella Weinberg Partners LP is acting as independent capital markets advisor to NovoCure Limited for the offering.

NovoCure Limited is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors called TTFields. Novocure’s US operations are based in Portsmouth, NH and New York, NY. Additionally, the company has offices in Germany, Switzerland, and Japan and a research center in Haifa, Israel.

You May Also Be Interested In

• YPF Energía Eléctrica S.A. files for proposed NYSE IPO
• Scribe Therapeutics Files for Nasdaq IPO
• IMC Rare Earths files for IPO on NYSE American